Kymera Therapeutics announced positive Phase 1 trial results for KT-579, showing deep IRF5 degradation and strong biomarker modulation with a good safety profile. The company plans to start a Phase 1b lupus trial for KT-579 by early 2027 and expects topline data from its KT-621 Phase 2b atopic dermatitis trial by year-end 2026. Kymera is well-funded with $1.6 billion in cash, providing a runway into 2029 to support ongoing clinical programs targeting autoimmune and inflammatory diseases.
Following Kymera Therapeutics' announcement of positive trial results and upcoming clinical milestones, its stock price on Pluang rose by 1.92% to USD 124.86 as of Oct 29, 2026 18:12 WIB. The company holds a market cap of $10.21 billion and is trading near its 52-week high of $127.31. Typical investors on Pluang hold KYMR shares for about 14 days, reflecting active interest in this health sector stock.
